Obesity and breast cancer: not only a risk factor of the disease (Q38436984)

3 September 2017

1 reference

title

Obesity and breast cancer: not only a risk factor of the disease (English)

1 reference

3 September 2017

0 references

0 references

2

Teresa Norat

1 reference

3 September 2017

Doris S M Chan

1

1 reference

3 September 2017

publication date

1 May 2015

1 reference

Current Treatment Options in Oncology

3 September 2017

published in

1 reference

3 September 2017

volume

16

1 reference

3 September 2017

issue

5

1 reference

3 September 2017

page(s)

22

1 reference

Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Today's lifestyles, tomorrow's cancers: trends in lifestyle risk factors for cancer in low- and middle-income countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Weight gain in women diagnosed with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Weight gain in breast cancer survivors: prevalence, pattern and health consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Body composition changes in females treated for breast cancer: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Weight loss in breast cancer patient management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Excess body weight and second primary cancer risk after breast cancer: a systematic review and meta-analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Quality of life of breast cancer patients with lymphedema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

The effect of comorbidity on 3-year survival of women with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Obesity, adipocytokines, and insulin resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Energy balance, host-related factors, and cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Minireview: Obesity and breast cancer: the estrogen connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Obesity and cancer: the role of dysfunctional adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

The two major epidemics of the twenty-first century: obesity and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Weight gain following breast cancer diagnosis: Implication and proposed mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Aromatase inhibitor-induced arthralgia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

American Society of Clinical Oncology position statement on obesity and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Obesity and mortality after breast cancer by race/ethnicity: The California Breast Cancer Survivorship Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Obesity and the outcome of young breast cancer patients in the UK: the POSH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Obesity is associated with a poorer prognosis in women with hormone receptor positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Triple-negative breast cancer: therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Outcome disparities in African American women with triple negative breast cancer: a comparison of epidemiological and molecular factors between African American and Caucasian women with triple negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Triple-negative breast cancer--current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Impact of body mass index on clinical outcomes in triple-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Association between African American race and outcomes in patients with nonmetastatic triple-negative breast cancer: a retrospective analysis by using results from the Georgia Cancer Specialist Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Does obesity have an effect on outcomes in triple-negative breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Body mass index, diabetes, and triple-negative breast cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Factors associated with mortality after breast cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Obesity is an independent predictor of poor survival in metastatic breast cancer: retrospective analysis of a patient cohort whose treatment included high-dose chemotherapy and autologous stem cell support

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Central adiposity after breast cancer diagnosis is related to mortality in the Health, Eating, Activity, and Lifestyle study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Neoadjuvant treatment of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Obesity and hormone therapy in breast cancer: an unfinished puzzle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

A decade of letrozole: FACE

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Obesity and endocrine therapy: host factors and breast cancer outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Diet, lifestyle, and the risk of type 2 diabetes mellitus in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Weight management and its role in breast cancer rehabilitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Association between physical activity and mortality among breast cancer and colorectal cancer survivors: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Effects of exercise during adjuvant chemotherapy on breast cancer outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Weight loss intervention trials in women with breast cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Effect of a diet and physical activity intervention on body weight and nutritional patterns in overweight and obese breast cancer survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Weight change and survival after breast cancer in the after breast cancer pooling project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

The German SUCCESS C Study - The First European Lifestyle Study on Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

American Cancer Society guidelines on nutrition and physical activity for cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

American College of Sports Medicine roundtable on exercise guidelines for cancer survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Body Mass Index and Prognosis of Metastatic Breast Cancer Patients Receiving First-Line Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0341-9

Nutrition and physical activity guidelines for cancer survivors

21 January 2018

1 reference

12 December 2020

Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer

1 reference

12 December 2020

Undertreatment of obese women receiving breast cancer chemotherapy

1 reference

12 December 2020

Exercise and dietary advice intervention for survivors of triple-negative breast cancer: effects on body fat, physical function, quality of life, and adipokine profile

1 reference

12 December 2020

Body mass and stage of breast cancer at diagnosis

1 reference

12 December 2020

The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women

1 reference

12 December 2020

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

1 reference

12 December 2020

Lifestyle and breast cancer recurrences: the DIANA-5 trial

1 reference

12 December 2020

Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age

1 reference

12 December 2020

Impact of body mass index on survival outcome among women with early stage triple-negative breast cancer

1 reference

12 December 2020

10.1007/S11864-015-0341-9

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

1015568854

0 references

1 reference